Bank of New York Mellon Corp decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 0.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 108,085 shares of the company’s stock after selling 772 shares during the quarter. Bank of New York Mellon Corp’s holdings in CRISPR Therapeutics were worth $6,068,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in shares of CRISPR Therapeutics by 158.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,014,551 shares of the company’s stock valued at $183,194,000 after acquiring an additional 1,848,437 shares during the period. State Street Corp increased its stake in CRISPR Therapeutics by 228.8% during the 2nd quarter. State Street Corp now owns 1,569,860 shares of the company’s stock valued at $95,400,000 after purchasing an additional 1,092,384 shares in the last quarter. BlackRock Inc. increased its stake in shares of CRISPR Therapeutics by 79.2% in the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock worth $143,038,000 after acquiring an additional 1,007,246 shares during the period. Vanguard Group Inc. boosted its holdings in CRISPR Therapeutics by 261.4% during the first quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company’s stock worth $76,410,000 after buying an additional 880,463 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in CRISPR Therapeutics by 33.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,993,577 shares of the company’s stock worth $121,689,000 after buying an additional 752,132 shares in the last quarter. Institutional investors own 68.20% of the company’s stock.
Wall Street Analysts Forecast Growth
CRSP has been the topic of several research reports. Credit Suisse Group raised their price target on shares of CRISPR Therapeutics from $62.00 to $63.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. Oppenheimer restated an “outperform” rating and issued a $102.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, August 10th. Mizuho began coverage on shares of CRISPR Therapeutics in a report on Tuesday, September 26th. They issued a “buy” rating and a $82.00 price objective for the company. Citigroup upgraded shares of CRISPR Therapeutics from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a report on Thursday, August 17th. Finally, Needham & Company LLC dropped their price objective on shares of CRISPR Therapeutics from $88.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $69.88.
CRISPR Therapeutics Trading Up 6.3 %
CRISPR Therapeutics stock opened at $72.18 on Tuesday. The stock has a market cap of $5.73 billion, a P/E ratio of -16.15 and a beta of 1.57. The stock has a 50 day moving average of $47.07 and a 200-day moving average of $53.29. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $76.19.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its quarterly earnings data on Monday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.04) by $0.63. CRISPR Therapeutics had a negative return on equity of 19.10% and a negative net margin of 240.84%. During the same quarter in the previous year, the firm earned ($2.24) EPS. As a group, equities analysts predict that CRISPR Therapeutics AG will post -3.59 earnings per share for the current fiscal year.
CRISPR Therapeutics Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Five stocks we like better than CRISPR Therapeutics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- The most upgraded stocks in November have two things in common
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Monday.com rocked earnings like it’s the weekend
- How to Invest in Insurance Companies: A Guide
- Plan to own one retailer? Make it this one
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.